Table 4 Refinement of the disease risk index (DRI, derived from Armand et al, reference 19) as applied to the first phase of the EBMT benchmarking system
Disease | Stage | DRI group |
|---|---|---|
Hodgkin lymphoma CR | Low | |
CLL CR | Low | |
Mantle cell lymphoma CR | Low | |
Indolent NHL CR | Low | |
AML favourable cytogenetics CR | Low | |
Indolent NHL PR | Low | |
CLL PR | Low | |
CML chronic phase 1/2 | Low | |
CML advanced phase | Int | |
Mantle cell lymphoma PR | Int | |
Myeloproliferative neoplasm | Any | Int |
AML intermediate cytogenetics CR | Int | |
ALL CR1 | Int | |
T-cell NHL CR | Int | |
Multiple myeloma CR/VGPR/PR | Int | |
Aggressive NHL CR | Int | |
Low-risk MDS adverse cytogenetics | Early† | Int |
T-cell NHL PR | Int | |
Low-risk MDS intermediate cytogenetics | Early† | Int |
Hodgkin lymphoma PR | Int | |
Low-risk MDS intermediate cytogenetics | Advanced† | Int |
Indolent NHL | Advanced† | Int |
CLL | Advanced | Int |
High-risk MDS intermediate cytogenetics | Early | Int |
Aggressive NHL PR | Int | |
T-cell NHL | Advanced† | High |
AML favourable cytogenetics | Advanced† | High |
Hodgkin lymphoma | Advanced† | High |
High-risk MDS intermediate cytogenetics | Advanced† | High |
High-risk MDS adverse cytogenetics | Early | High |
ALL CR2 | High | |
AML adverse cytogenetics CR | High | |
Mantle cell lymphoma | Advanced† | High |
High-risk MDS adverse cytogenetics | Advanced† | High |
Burkitt lymphoma CR | High | |
Multiple myeloma | Advanced† | High |
ALL CR3 | High | |
Low-risk MDS adverse cytogenetics | Advanced† | High |
AML intermediate cytogenetics | Advanced | High |
CML blast phase | Very high | |
ALL | Advanced† | Very high |
Aggressive NHL | Advanced† | Very high |
AML adverse cytogenetics | Advanced† | Very high |
Burkitt lymphoma PR | Advanced† | Very high |
